China Depression Screening Mental Health Market

Key Players: UnitedHealth Group (US), Anthem (US), Cigna (US), Kaiser Permanente (US), Teladoc Health (US), Mayo Clinic (US), HCA Healthcare (US), Cerner Corporation (US)

China Depression Screening Mental Health Market

China Depression Screening Mental Health Market Research Report: Size, Share, Trend Analysis By Indication (Major Depressive Disorder, Anxiety Distress, Bipolar Disorder, Psychotic Disorders, Others), By Diagnosis (Psychological Tests, Blood Tests, Pharmacogenomic Testing, Others) and By End Users (Hospitals and Clinics, Home-based, Research and Academic Institutes) - Growth Outlook & Industry Forecast 2025 To 2035
ID: MRFR/HC/54524-HCR
200 Pages
Satyendra Maurya, Rahul Gotadki
Last Updated: February 06, 2026

China Depression Screening Mental Health Market Summary

As per Market Research Future analysis, the China Depression Screening Mental Health Market size was estimated at 54.79 USD Million in 2024. The China Depression Screening Mental Health Market is projected to grow from 58.01 USD Million in 2025 to 102.63 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 5.8% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The China Depression Screening Mental Health Market is experiencing significant growth. This growth is driven by technological advancements and increased awareness.

  • The largest segment in the market is digital screening tools, which are witnessing increased adoption across various demographics.
  • The fastest-growing segment is preventive care services, reflecting a shift towards early intervention in mental health.
  • Government support and policy development are fostering a more robust framework for mental health services in China.
  • Rising mental health awareness and technological advancements in screening tools are key drivers propelling market growth.

Market Size & Forecast

2024 Market Size 54.79 (USD Million)
2035 Market Size 102.63 (USD Million)
CAGR (2025 - 2035) 5.87%

Major Players

UnitedHealth Group (US), Anthem (US), Cigna (US), Kaiser Permanente (US), Teladoc Health (US), Mayo Clinic (US), HCA Healthcare (US), Cerner Corporation (US)

Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

China Depression Screening Mental Health Market Drivers

Rising Mental Health Awareness

The increasing awareness of mental health issues in China is a crucial driver for the depression screening mental health market. Public campaigns and educational initiatives have contributed to a growing understanding of depression and its impact on individuals and society. As a result, more people are seeking screening and treatment options. According to recent surveys, approximately 16% of the Chinese population experiences depressive symptoms, highlighting the need for effective screening methods. This heightened awareness is likely to drive demand for mental health services, thereby expanding the market. Furthermore, the stigma surrounding mental health is gradually diminishing, encouraging individuals to seek help. The depression screening mental health market is poised to benefit from this cultural shift, as more individuals recognize the importance of mental well-being and actively pursue screening and treatment.

Rising Prevalence of Depression Among Youth

The rising prevalence of depression among the youth population in China is a critical driver for the depression screening market. Recent studies indicate that nearly 25% of adolescents report experiencing depressive symptoms, prompting a need for effective screening and intervention strategies. This demographic shift highlights the urgency for mental health services tailored to younger individuals. Schools and universities are increasingly recognizing the importance of mental health support, leading to the implementation of screening programs within educational institutions. As awareness grows and more young people seek help, the depression screening mental health market is likely to expand significantly. This trend underscores the necessity for targeted approaches to address the unique mental health challenges faced by the youth.

Increased Funding for Mental Health Services

The Chinese government has recognized the importance of mental health and is increasing funding for mental health services, which serves as a significant driver for the depression screening mental health market. In recent years, government expenditure on mental health has risen, with a focus on improving access to screening and treatment. Reports indicate that funding for mental health initiatives has increased by approximately 20% annually, reflecting a commitment to addressing mental health issues. This financial support enables the development of more comprehensive screening programs and the training of healthcare professionals. As a result, the depression screening mental health market is likely to expand, as more resources become available to facilitate early detection and intervention for depression.

Technological Advancements in Screening Tools

Technological innovations are transforming the landscape of the depression screening mental health market in China. The development of advanced screening tools, including mobile applications and online platforms, facilitates easier access to mental health assessments. These tools often utilize artificial intelligence and machine learning algorithms to provide accurate evaluations of depressive symptoms. As of 2025, it is estimated that over 30% of mental health screenings in urban areas are conducted through digital platforms. This trend not only enhances the efficiency of screening processes but also reaches a broader audience, particularly among younger populations who are more tech-savvy. The integration of technology into mental health services is likely to drive growth in the depression screening mental health market, as it offers convenient and timely access to necessary resources.

Integration of Mental Health into Primary Care

The integration of mental health services into primary care settings is emerging as a vital driver for the depression screening market in China. This approach allows for a more holistic view of patient health, where mental health screenings are conducted alongside physical health assessments. As of November 2025, approximately 40% of primary care facilities in urban areas are implementing mental health screening protocols. This integration not only improves access to mental health services but also encourages early detection of depressive symptoms. By normalizing mental health discussions within primary care, the stigma associated with seeking help is further reduced. Consequently, the depression screening mental health market is expected to grow as more individuals receive timely screenings and appropriate referrals for treatment.

Market Segment Insights

By Indication: Major Depressive Disorder (Largest) vs. Anxiety Distress (Fastest-Growing)

In the China depression screening-mental-health market, the market share distribution among the indication values shows that Major Depressive Disorder holds the largest share, reflecting the significant prevalence and recognition of this condition. In contrast, Anxiety Distress is showing a marked increase in share, indicating a shifting awareness and focus on this increasingly relevant mental health issue. Growth trends for these segments are driven by various factors, including an increasing willingness to seek professional help, the rising awareness of mental health issues among the public, and the growing number of private and public initiatives aimed at improving mental health services. With societal stigma reducing, more individuals are being diagnosed and treated, particularly in the segment of Anxiety Distress, which is gaining traction as a significant area of concern in mental health discussions.

Major Depressive Disorder (Dominant) vs. Anxiety Distress (Emerging)

Major Depressive Disorder remains the dominant segment in the China depression screening-mental-health market, characterized by a well-established diagnosis and treatment framework which attracts substantial funding and research. Patients within this category often require comprehensive, long-term management strategies that include psychotherapy and medication. Conversely, Anxiety Distress is emerging as a crucial segment, marked by a growing incidence rate and a rising demand for screening tools. The latter's rapid growth can be attributed to increased public awareness and changing societal attitudes towards mental health. Efforts to address this rising trend include expanding therapeutic options and integrating anxiety disorder screenings into primary healthcare systems. Both segments reflect the evolving landscape of mental health challenges in China.

By Diagnosis: Psychological Tests (Largest) vs. Blood Tests (Fastest-Growing)

In the China depression screening-mental-health market, Psychological Tests account for the largest share among various testing methods, showcasing their significance in diagnosing depression effectively. Blood Tests are rapidly gaining traction, although they currently represent a smaller market segment compared to Psychological Tests, indicating a shift towards a more diversified approach to mental health assessment. The growth trends in this sector reveal increasing adoption of advanced Psychological Tests driven by a greater understanding of mental health issues and improved healthcare policies focusing on mental wellbeing. Blood Tests are emerging as a promising alternative, accelerated by technological advancements that make these tests more accessible and efficient, thereby reshaping the traditional landscape of diagnostic methods in mental health.

Psychological Tests: Dominant vs. Blood Tests: Emerging

Psychological Tests hold a dominant position in the market, reflecting their established efficacy in diagnosing depression. These tests often involve standardized questionnaires that assess various psychological aspects, making them widely accepted among clinicians. On the other hand, Blood Tests represent an emerging market segment, appealing to both healthcare providers and patients looking for innovative solutions. They provide biochemical insights and could complement traditional methods, helping in more holistic patient assessments. The increasing awareness of mental health issues in society supports the growth of both segments, facilitating a broader array of options for diagnosis.

By End User: Hospitals and Clinics (Largest) vs. Home-based (Fastest-Growing)

In the China depression screening-mental-health market, the end user segment is predominantly led by hospitals and clinics, making up a significant share due to their established infrastructure and comprehensive services. Home-based solutions are rapidly gaining traction as more individuals seek accessible mental health resources from the comfort of their own environments. This shift is markedly influenced by the increasing awareness of mental health issues and the growing acceptance of telemedicine initiatives. The growth trends within this segment are driven by several factors, including a rise in mental health awareness and the stigma reduction surrounding mental health issues. Additionally, innovations in digital health technologies are promoting home-based screening, providing patients with flexibility and privacy. Research and academic institutes play a supportive role, contributing to evidence-based approaches that enhance service delivery across both dominant and emerging segments.

Hospitals and Clinics (Dominant) vs. Home-based (Emerging)

Hospitals and clinics hold a dominant position in the China depression screening-mental-health market, characterized by their comprehensive diagnostic facilities and access to trained mental health professionals. These institutions benefit from established trust and recognition in the community, often being the first point of contact for patients seeking help. In contrast, home-based solutions are emerging rapidly, facilitated by technological advancements that allow for remote screenings and consultations. This segment is particularly appealing to younger populations who value convenience and privacy, thus reshaping the traditional model of mental health services. As both segments evolve, the interplay between in-person and home-based solutions may redefine patient care strategies in the mental health landscape.

Get more detailed insights about China Depression Screening Mental Health Market

Key Players and Competitive Insights

The depression screening-mental-health market in China is characterized by a rapidly evolving competitive landscape, driven by increasing awareness of mental health issues and a growing demand for accessible screening solutions. Key players are strategically positioning themselves through innovation, partnerships, and digital transformation to capture market share. Notably, companies such as UnitedHealth Group (US), Cigna (US), and Teladoc Health (US) are focusing on enhancing their service offerings and expanding their reach within the region, thereby shaping a competitive environment that emphasizes both quality and accessibility of mental health services.In terms of business tactics, companies are increasingly localizing their operations to better cater to the unique needs of the Chinese market. This includes optimizing supply chains and leveraging local partnerships to enhance service delivery. The market appears moderately fragmented, with several key players exerting influence, yet the collective actions of these companies suggest a trend towards consolidation as they seek to enhance their competitive edge.
In October UnitedHealth Group (US) announced a partnership with a leading Chinese telehealth provider to expand its mental health services, aiming to integrate advanced AI-driven screening tools into their platform. This strategic move is likely to enhance their service delivery and improve patient outcomes, reflecting a broader trend towards the integration of technology in mental health care.
In September Cigna (US) launched a new initiative focused on mental health awareness and screening in urban areas of China, collaborating with local health authorities. This initiative not only aims to increase access to mental health resources but also positions Cigna as a proactive player in addressing mental health challenges, potentially leading to increased market penetration and brand loyalty.
In August Teladoc Health (US) expanded its mental health services by acquiring a local mental health startup, which specializes in digital therapy solutions. This acquisition is indicative of a growing trend towards digitalization in mental health care, allowing Teladoc to enhance its service offerings and cater to a tech-savvy population seeking convenient mental health solutions.
As of November the competitive trends in the depression screening-mental-health market are increasingly defined by digitalization, AI integration, and strategic alliances. Companies are moving towards a landscape where innovation and technology play pivotal roles in differentiation. The shift from price-based competition to a focus on quality, reliability, and technological advancement is evident, suggesting that future competitive dynamics will hinge on the ability to innovate and adapt to the evolving needs of consumers.

Key Companies in the China Depression Screening Mental Health Market include

Industry Developments

The China Depression Screening Mental Health Market has witnessed notable advancements recently. Significant emphasis is being placed on integrating technology into mental health solutions, with companies like Mindray and HC Medical enhancing their screening capabilities through innovative tools such as artificial intelligence. In September 2023, Hongyun Medical announced the launch of a new digital platform aimed at streamlining depression screenings across hospitals in China. Financially, the market is experiencing growth, with industry evaluations reaching approximately USD 2 billion, driven by increasing government initiatives to improve mental health services and the rising awareness of mental health issues among Chinese citizens. 

Moreover, there have been essential mergers and acquisitions, such as the strategic partnership formed in August 2023 between Beijing Yikang and Chengdu Mindlight to strengthen their product offerings. Overall, the industry is evolving rapidly, with organizations like Zhuoma Technology and Xiangyu Medical exploring collaborative efforts to expand their reach in mental health services. Recent investments point towards a robust demand for accurate depression screening methods in response to the rising patient population across China.

 

Future Outlook

China Depression Screening Mental Health Market Future Outlook

The Depression Screening Mental Health Market is projected to grow at a 5.87% CAGR from 2025 to 2035, driven by increasing awareness and technological advancements.

New opportunities lie in:

  • Development of AI-driven diagnostic tools for early detection. Expansion of telehealth services for remote patient monitoring. Integration of mental health screening in primary care settings.

By 2035, the market is expected to achieve substantial growth and innovation.

Market Segmentation

China Depression Screening Mental Health Market End User Outlook

  • Hospitals and Clinics
  • Home-based
  • Research and Academic Institutes

China Depression Screening Mental Health Market Diagnosis Outlook

  • Psychological Tests
  • Blood Tests
  • Pharmacogenomic Testing
  • Others

China Depression Screening Mental Health Market Indication Outlook

  • Major Depressive Disorder
  • Anxiety Distress
  • Bipolar Disorder
  • Psychotic Disorders
  • Others

Report Scope

MARKET SIZE 2024 54.79(USD Million)
MARKET SIZE 2025 58.01(USD Million)
MARKET SIZE 2035 102.63(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 5.87% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled UnitedHealth Group (US), Anthem (US), Cigna (US), Kaiser Permanente (US), Teladoc Health (US), Mayo Clinic (US), HCA Healthcare (US), Cerner Corporation (US)
Segments Covered Indication, Diagnosis, End User
Key Market Opportunities Integration of digital health solutions enhances accessibility in the depression screening-mental-health market.
Key Market Dynamics Rising demand for digital mental health solutions drives innovation in depression screening methodologies and technologies.
Countries Covered China

FAQs

What was the market valuation of the China depression screening-mental-health market in 2024?

The market valuation was $54.79 Million in 2024.

What is the projected market valuation for the China depression screening-mental-health market by 2035?

The projected valuation for 2035 is $102.63 Million.

What is the expected CAGR for the China depression screening-mental-health market during the forecast period 2025 - 2035?

The expected CAGR is 5.87% during the forecast period 2025 - 2035.

Which key players are leading the China depression screening-mental-health market?

Key players include UnitedHealth Group, Anthem, Cigna, Kaiser Permanente, Teladoc Health, Mayo Clinic, HCA Healthcare, and Cerner Corporation.

What are the major segments of the China depression screening-mental-health market?

Major segments include Major Depressive Disorder, Anxiety Distress, Bipolar Disorder, Psychotic Disorders, and Others.

What was the market size for Major Depressive Disorder in 2024?

The market size for Major Depressive Disorder was $20.0 Million in 2024.

What is the projected market size for Psychological Tests by 2035?

The projected market size for Psychological Tests is expected to reach $38.0 Million by 2035.

How does the market size for Home-based services compare to Hospitals and Clinics in 2024?

In 2024, Home-based services had a market size of $15.0 Million, while Hospitals and Clinics reached $20.0 Million.

What is the expected growth for Pharmacogenomic Testing in the China depression screening-mental-health market?

Pharmacogenomic Testing is projected to grow from $5.0 Million in 2024 to $10.0 Million by 2035.

What are the anticipated trends in the end-user segment of the China depression screening-mental-health market?

The end-user segment is expected to show growth, particularly in Research and Academic Institutes, which had a market size of $19.79 Million in 2024.

Author
Author
Author Profile
Satyendra Maurya LinkedIn
Research Analyst
An accomplished research analyst with high proficiency in market forecasting, data visualization, competitive benchmarking, and others. He holds a pronounced track record in research and consulting projects for sectors such as life sciences, medical devices, and healthcare IT. His capabilities in qualitative and quantitative analysis have resulted in positive client outcomes. Working on niche market trends, opportunities, sales, and forecasted value is part of his skill set.
Co-Author
Co-Author Profile
Rahul Gotadki LinkedIn
Research Manager
He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.
Leave a Comment
Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.